Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lineage Cell Therapeutics (LCTX) Accounts Payables: 2010-2025

Historic Accounts Payables for Lineage Cell Therapeutics (LCTX) over the last 15 years, with Sep 2025 value amounting to $4.5 million.

  • Lineage Cell Therapeutics' Accounts Payables rose 1.63% to $4.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $4.5 million, marking a year-over-year increase of 1.63%. This contributed to the annual value of $5.4 million for FY2024, which is 13.29% down from last year.
  • According to the latest figures from Q3 2025, Lineage Cell Therapeutics' Accounts Payables is $4.5 million, which was up 2.22% from $4.5 million recorded in Q2 2025.
  • Over the past 5 years, Lineage Cell Therapeutics' Accounts Payables peaked at $28.0 million during Q4 2021, and registered a low of $4.5 million during Q2 2025.
  • For the 3-year period, Lineage Cell Therapeutics' Accounts Payables averaged around $5.1 million, with its median value being $5.0 million (2024).
  • In the last 5 years, Lineage Cell Therapeutics' Accounts Payables spiked by 310.52% in 2021 and then slumped by 69.22% in 2022.
  • Over the past 5 years, Lineage Cell Therapeutics' Accounts Payables (Quarterly) stood at $28.0 million in 2021, then slumped by 69.22% to $8.6 million in 2022, then declined by 27.16% to $6.3 million in 2023, then dropped by 13.29% to $5.4 million in 2024, then rose by 1.63% to $4.5 million in 2025.
  • Its last three reported values are $4.5 million in Q3 2025, $4.5 million for Q2 2025, and $5.0 million during Q1 2025.